Fundraising Fox
Chemomab
Tel Aviv · Founded 2011 · 20 employees on LinkedIn · 3 known investors
Find your way into Chemomab
Each arrow is one introduction. Sign up to fill in the first one.
Ask Mitch Jones to introduce you to Arnon Aharon
You →Mitch · together at Chemomab →Arnon
Ask Jamie Chen to introduce you to Jill Quigley
You →Jamie · together at Terns Pharmaceuticals →Jill
Ask Sam Okafor to introduce you to Matthew Frankel
You →Sam · together at Nocion Therapeutics →Matthew
Sign up to find every way you can get introduced to Chemomab
- Your email: who you already know at Chemomab, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Chemomab team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis. The company focuses on anti-fibrotic and anti-inflammatory treatments for patients with fibrotic diseases.
Founders & leadership
Chemomab was founded in 2011 by Adi Mor and Adi Mor George.
Board
Investors · 3
How we know: Altium Capital's portfolio page · Not right? Tell us
How we know: OrbiMed's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$55.4M disclosed across 2 of 3 rounds · 2021–2026
▶$10MraisedAug 2024 · 10 investors · BiotechnologyRule 506(b)
- Neil Harris CohenDirector
- Jill QuigleyDirector
- Sigal FattalExecutive Officer
- Adi MorExecutive Officer, Director
- Alan Charles MosesDirector
- Matthew FrankelExecutive Officer
- Claude NicaiseDirector
- Nissim DarvishDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $400K
- Placement agents
- Oppenheimer & Co. Inc.
- First sale
- Jul 2024
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$45.4MraisedMar 2021 · 26 investors · BiotechnologyRule 506(b)
- Adi Mor GeorgeExecutive Officer, Director
- Arnon AharonExecutive Officer
- Neil Harris CohenDirector
- Joel Michael MarylesDirector
- Nissim DarvishDirector
- Claude NicaiseDirector
- Sigal FatalExecutive Officer
- Stephen P SquintoDirector
- Moses Charles AlanDirector
- Offering amount
- $45.4M
- Amount sold
- $45.4M
- Sales commissions
- $1.6M
- Placement agents
- Oppenheimer & Co. Inc.
- First sale
- Mar 2021
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Chemomab do?
- Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis. The company focuses on anti-fibrotic and anti-inflammatory treatments for patients with fibrotic diseases.
- Who founded Chemomab?
- Chemomab was founded by Adi Mor, Adi Mor George in 2011.
- Who are Chemomab's investors?
- Chemomab's investors include Altium Capital, OrbiMed, SBI JI Innovation Advisory Ltd..
- How much funding has Chemomab raised?
- Chemomab has disclosed $55.4M raised across 2 of its 3 known rounds.
- Where is Chemomab headquartered?
- Chemomab is headquartered in Tel Aviv.